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The class II transactivator (CIITA) is a master transcriptional regulator of major histocompatibility
complex class II (MHC-II) promoters. CIITA does not bind DNA, but it interacts with the transcription factors
RFX5, NF-Y, and CREB and associated chromatin-modifying enzymes to form an enhanceosome. This report
examines the effects of histone deacetylases 1 and 2 (HDAC1/HDAC2) on MHC-II gene induction by gamma
interferon (IFN-) and CIITA. The results show that an inhibitor of HDACs, trichostatin A, enhances
IFN--induced MHC-II expression, while HDAC1/HDAC2 inhibits IFN-- and CIITA-induced MHC-II gene
expression. mSin3A, a corepressor of HDAC1/HDAC2, is important for this inhibition, while NcoR, a core-
pressor of HDAC3, is not. The effect of this inhibition is directed at CIITA, since HDAC1/HDAC2 reduces
transactivation by a GAL4-CIITA fusion protein. CIITA binds to overexpressed and endogenous HDAC1,
suggesting that HDAC and CIITA may affect each other by direct or indirect association. Inhibition of HDAC
activity dramatically increases the association of NF-YB and RFX5 with CIITA, the assembly of CIITA, NF-YB,
and RFX5 enhanceosome, and the extent of H3 acetylation at the MHC-II promoter. These results suggest a
model where HDAC1/HDAC2 affect the function of CIITA through a disruption of MHC-II enhanceosome and
relevant coactivator-transcription factor association and provide evidence that CIITA may act as a molecular
switch to modulate MHC-II transcription by coordinating the functions of both histone acetylases and HDACs.
Class II major histocompatibility complex (MHC-II) pro-
teins play a central role in the control of normal immune
homeostasis, while aberrant expression of MHC-II is fre-
quently associated with abnormalities in immune responses.
MHC-II proteins elicit immune activation through presenta-
tion of exogenously derived antigens to CD4 T cells and
represent the seminal control of both peripheral T-cell activa-
tion and thymic selection (23, 28, 47). The level of MHC-II
expression is exquisitely regulated. Constitutive MHC-II ex-
pression is restricted to B cells, monocytes, macrophages, and
dendritic cells, whereas inducible expression is observed on a
selected number of cell types in response to cytokines such as
gamma interferon (IFN-) and tumor necrosis factor alpha
(TNF-) (37, 47). The regulation of MHC-II expression re-
sides predominantly at the transcriptional level and is global-
ly controlled by the master regulator, class II transactivator
(CIITA) (12, 47).
CIITA was initially isolated by complementation cloning,
using an Epstein-Barr virus-based library to rescue MHC-II
expression in MHC-II-negative cells (45). CIITA is encoded by
the MHC2TA gene, deletions in which represent the genetic
defect in immunodeficient type II group A bare lymphocyte
syndrome patients. Expression of CIITA is controlled by four
distinct promoters, allowing for a complex pattern of constitu-
tive and inducible MHC-II expression (31, 39). CIITA does not
bind DNA but controls MHC-II and related genes by interact-
ing with the requisite MHC-II transcription factors (RFX5,
CREB, and NF-Y), which associate with conserved promoter
motifs, termed X1, X2, and Y, respectively (9, 26, 29, 42, 58).
These interactions are critical for the formation of a stable
enhanceosome. CIITA also interacts with components of the
basal transcription machinery (TFIIB, TATA binding protein,
and TATA binding protein-associated factors) (6, 25, 27).
Most relevant to this work, CIITA associates with several chro-
matin remodeling enzymes, including histone acetyltransfer-
ases (HATs) CBP/p300, and pCAF (16, 43, 44, 59), and ATP-
dependent remodeling factors, such as BRG-1 (30, 38). These
enzymes have all been demonstrated to modulate MHC-II
promoter activation.
Structure-function analysis of CIITA protein indicates that it
can be divided into three important segments. The N terminus
contains an acidic transactivation domain as well as target
lysines for both acetylases and a HAT-like domain (16, 40, 44).
The mid-section contains a nucleotide-binding domain (NBD)
that is critical for nuclear import and contributes to self-asso-
ciation (10, 17, 21). The C terminus contains a stretch of
leucine-rich repeats (LRRs) that are also involved in protein-
protein association (11, 21). This unique combination of the
NBD and LRR domains is a conserved feature among a new
family of known and novel genes, which we have recently called
the CATERPILLER family (11). The NBD domain is also
shared by a more loosely related family of known genes, called
the NACHT family. Members of this family range from plant
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to mammal proteins with a shared NBD domain and either an
LRR motif or a WD40 motif at its C terminus. In addition to
these three segments, sequences important for nuclear import
controlled by different types of nuclear localization signal (4, 5,
17) are scattered throughout the protein. To a lesser extent,
nuclear export sequences have also been found (5, 17).
The molecular mechanism by which CIITA regulates the
expression of MHC-II genes is an area of intense interest.
CIITA is known to mediate chromatin alterations necessary
for promoter accessibility, as demonstrated by in vivo foot-
printing studies of MHC-II, invariant chain, and HLA-DM
promoters in non-B cells (22, 51–53). These studies showed
that these promoters are “closed” in the absence of CIITA,
with little if any detectable binding by X and Y box binding
factors (i.e., RFX or NF-Y). Both IFN- and CIITA can in-
duce an open chromatin structure (52, 53). This observation is
indicative of chromatin remodeling activity, which could be
mediated directly by CIITA or by the recruitment of specific
remodeling factors, such as HATs. Interestingly, CIITA also
possesses its own intrinsic HAT activity in its N terminus,
which may contribute to chromatin remodeling (40). In further
support of a role for CIITA in chromatin remodeling, a recent
study has reported the correlation of recruitment of CIITA
with increased acetylation of histones H3 and H4 at the en-
dogenous MHC-II promoter (3).
While the role of HATs in CIITA-mediated activation of
MHC-II has become more evident, the implication of deacety-
lation in this process is just emerging. Generally, histone
deacetylation correlates with transcriptional repression and is
mediated by distinct histone deacetylase (HDAC) complexes
(8, 49). The mammalian HDACs identified so far fall into
three groups: the yeast RPD3 protein-like HDACs (HDACs 1,
2, 3, and 8), the yeast HDA1 protein-like HDACs (HDACs 4,
5, 6, 7, and 9), and the sirtuin deacetylases, which require NAD
as a substrate (8). HDAC1 and HDAC2 are the best charac-
terized of the HDAC proteins. HDAC1 was first isolated by
affinity chromatography using the HDAC inhibitor trapoxin
(46), whereas HDAC2 was identified in a yeast two-hybrid
screening using YY1 transcription factor as bait (54). Both
HDAC1 and HDAC2 stably associate with the mSin3A core-
pressor (2, 34). This complex can be recruited to specific
promoters via interactions with an array of sequence-specific
transcription factors, including unliganded hormone receptors
(RAR and TR) and p53 (15, 32). HDAC1 and HDAC2 are
also components of the nucleosome-remodeling HDAC com-
plex, which has been implicated in repression by DNA meth-
ylation (35).
A role of HDACs in MHC-II gene control has begun to
emerge, although the details have not been delineated. A gen-
eral HDAC inhibitor (trichostatin A [TSA]) can rescue MHC-
II expression in tumor cells and mature dendritic cells where
MHC-II transcription is normally repressed (18, 24). Similarly,
in a system where MHC-II is inhibited in the absence of the
retinoblastoma protein (Rb), TSA treatment restored expres-
sion, and YY1, a repressor known to interact with HDAC1,
HDAC2 and HDAC3 (54), was implicated in mediating re-
pression (36). Although these observations suggest a role for
HDACs in MHC-II regulation, the part played by specific
HDACs is not yet clear.
In this report, we demonstrate that HDAC1 and HDAC2
specifically inhibit the transactivation function of CIITA and
the expression of endogenous MHC-II. This inhibition is con-
tingent upon an intact HDAC domain in HDAC1 and is even
more profound when mSin3A, an HDAC1-, HDAC2-associ-
ated repressor, is present. TSA, a potent inhibitor of HDAC
activity, dramatically enhances interactions of CIITA with
RFX5 and NF-Y, resulting in substantial increase of transcrip-
tion. TSA also promotes association of NF-YB and RFX5 with
the MHC-II promoter, thereby enhancing recruitment of
CIITA. Our findings strongly suggest that Sin3A-associated
HDAC1 and HDAC2 are involved in the repression of CIITA-
mediated MHC-II transcription through interference with en-
hanceosome assembly and coactivator (CIITA) interaction
with DNA-binding factors (NF-YB and RFX5), providing the
basis for a novel mechanism of MHC-II gene regulation.
MATERIALS AND METHODS
Tissue culture cells and conditions. COS 7, 293T, and HeLa cells were main-
tained in Dulbecco modified Eagle medium (high glucose) supplemented with
10% fetal calf serum, 5 mM L-glutamine, and streptomycin-penicillin. All cells
were grown at 37°C with 5% CO2.
Plasmids. The following plasmids have been described previously: Fg-CIITA,
Myc-CIITA Fg-RFX5, Fg-NF-YB, DRA300Luc, and Gal5Luc reporter (4, 5,
58). GFP-CIITA was constructed by standard PCR and recombinant DNA
methods. Fg-HDAC1, Fg-HDAC2, pIRESHis-mSin3A, and pCEP4-NcoR were
kindly provided by A. Baldwin (1). GAL4-CIITA (pSGCIITA) was a gift from
Jeremy Boss (41). HDAC1 (H199F) was a kind gift from Ed Seto (15).
Transfection and promoter assays. COS 7 cells (0.5  105 to 1  105) were
plated in six-well tissue culture plates and then transfected 18 to 24 h later using
FuGene 6 transfection reagent (Roche Molecular Biochemicals, Indianapolis,
Ind.) according to the manufacturer’s instructions. At 24 h post-transfection,
cells were lysed in 1 reporter lysis buffer (Promega, Madison, Wis.), and
luciferase assays were performed as previously described (39).
Immunoprecipitation and Western blotting. COS 7 or 293T cells were plated
(1.5  106 cells per 100-mm plate) 24 h prior to transfection. Cells were trans-
fected with 3 g of each expression vector using Fugene 6 (Roche) according to
the manufacturer’s recommendations. At 18 to 24 h posttransfection, the cells
FIG. 1. Global inhibition of deacetylation by TSA enhances the
inducible expression of MHC-II. Real-time PCR analysis was per-
formed to measure endogenous mRNA levels of MHC-II after IFN-
induction. HeLa cells were induced with 500 U of IFN-/ml for a time
course of 24 h and treated with 100 nM TSA. Values represent the
averages for three experiments. Samples were normalized to number
of GAPDH copies.
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were lysed with RIPA lysis buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM dithio-
threitol) supplemented with protease inhibitors (Complete EDTA-free; Roche).
Samples were lysed for 1 h on ice, centrifuged for 10 min, precleared with 50 l
of goat anti-mouse M-450-conjugated Dynabeads (Dynal, Oslo, Norway), and
immunoprecipitated for 1 h at 4°C with 5 g of anti-Fg M5 (Sigma, St. Louis,
Mo.). Immune complexes were isolated with 50 l of goat anti-mouse M-450
Dynabeads overnight at 4°C. Immunoprecipitated proteins were denatured using
Laemmli buffer, and the samples were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. The gels were transferred to nitrocellulose
and immunoblotted with primary antibody anti-Fg M5 (Sigma) or anti-Myc 9E10
(Upstate Biotechnology, Lake Placid, N.Y.) and horseradish peroxidase-conju-
gated secondary goat anti-mouse antibody (Santa Cruz Biotechnology, Santa
Cruz, Calif.). Horseradish peroxidase detection was performed using Supersignal
West Pico Chemiluminescent substrate (Pierce, Rockford, Ill.).
ChIP assays. Chromatin from 2  106 to 5  106 cells was cross-linked with
1% formaldehyde for 10 min at room temperature. Cross-linking was stopped by
the addition of 0.125 M glycine for 5 min at room temperature. After lysis, the
cross-linked chromatin was sheared to an average size of 500 to 1,000 bp by
sonication. Chromatin immunoprecipitations (ChIP) were performed using the
ChIP Assay kit (Upstate Biotechnology) according to the manufacturer’s rec-
ommendations. Each chromatin preparation was diluted 1:2, and immunopre-
cipitation was carried out with 5 g of anti-Fg M5 or 5 l of anti-acetyl-histone
H3 antibodies (Upstate Biotechnology). In addition, no-antibody control immu-
noprecipitations were also performed. Cross-links were reversed overnight at
65°C. Analysis of the immunoprecipitated products was done by real-time PCR
(see the section below) for the MHC-II promoter or by PCR for the -actin
promoter. In these reactions PCR was carried out for 40 cycles on 1/10 of the
immunoprecipitated products, as previously described (36).
Real-time PCR. cDNA was synthesized as described previously (50). Real-time
PCR was performed using the ABI Prism 7900 sequence detection system (Per-
kin-Elmer, Foster City, Calif.). MHC-II probes were labeled at the 5 end with
the reporter dye FAM and at the 3 end with the quencher dye TAMRA. The
18S rRNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probes
were labeled at the 5 end with the reporter dye TET and at the 3 end with the
quencher dye TAMRA. Primer and probe sequences are as follows: MHC-II
probe, 5-6 FAM-CTCCGATCACCAATGTACCTCCAGA-TAMRA-3; sense
primer, 5-AAGCCAACCTGGAAATCA-3; antisense primer, 5-GGCTGTTC
GTGAGCACAGTT-3; GAPDH probe, 5-6 FAM-CAAGCTTCCCGTTCT-
CAGCC-TAMRA-3; sense primer, 5-ACCTCAACTACATGGTTTAC-3; an-
tisense primer, 5-GAAGATGGTGATGGGATTTC-3; 18S rRNA probe, 5-6
FAM-CAAATTACCCACTCCCGACCCG-TAMRA-3; sense primer, 5-GCTG
CTGGCACCAGACTT-3; and antisense primer, 5-CGGCTACCACATCCAA
GG-3. Real-time PCR analysis of cDNA specimens was conducted as previously
FIG. 2. HDAC1 and HDAC2 repress CIITA transactivation function. (A) HDAC1 and HDAC2 repress MHC-II promoter activation. COS 7
cells were cotransfected with 100 ng of CIITA, 1 g of either HDAC1 or HDAC2, and 0.5 g of MHC-II–luciferase reporter. Luciferase activity
is reported as percent activation relative to that by CIITA alone. (B) HDAC1 and HDAC2 repress a Gal4-CIITA construct. Transfection was
performed as described for panel A. (C) Overexpression of HDAC1 does not affect Gal4-VP16 activation. Transfection was performed as described
for panel A. Values are shown as mean percent relative luciferase activity  standard error of the mean for three experiments, each of which was
repeated in triplicate. pSG424 is the empty vector control for Gal4 CIITA and Gal4-VP16. (D) HDAC1 or HDAC2 overexpression does not affect
CIITA protein levels. Equal amounts of Fg-CIITA and pcDNA3 (top panel, lane 1) or HDAC1 (top panel, lane 2) and HDAC2 (top panel, lane
3) were transfected in COS 7 cells, and Western analysis was performed using anti-Fg antibodies. As a loading control we also immunoblotted with
antibodies against actin (bottom panel).
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described (50). Values were calculated based on standard curves generated for
each gene. Normalization of samples was determined by dividing copies of
MHC-II by copies of GAPDH or 18S rRNA.
Real-Time PCR analysis of chromatin-immunoprecipitated products was per-
formed using the following MHC-II promoter primers and probe: MHC-II pro-
moter probe, 5-6 FAM-CTGGACCCTTTGCAAGAACCCTTCCC-TAMRA-
3; sense primer, 5-TCCAATGAACGGAGTATCTTGTGT-3; and antisense
primer, 5-TGAGATGACGCATCTGTTGCT-3.
Immunofluorescence microscopy. Immunofluorescent staining of transiently
transfected COS 7 cells was performed as previously described (4). Briefly, 8 
104 cells were grown overnight and transfected with 1.0 g of GFP-CIITA and
1.0 g of HDAC1 or HDAC2 using the FuGene 6 transfection reagent (Roche).
Following fixation with 60% acetone in phosphate-buffered saline, photomicro-
graphs were acquired using Scion Series 7 video capture hardware and an
Olympus BX40 fluorescence microscope.
RESULTS
TSA enhances inducible expression of endogenous MHC-II.
Inhibition of histone deacetylation has been correlated with
transcriptional activation (2, 8). Previous reports have shown
that TSA, a potent inhibitor of HDAC activity, can rescue
MHC-II expression in mouse and human tumor cell lines as
well as mature mouse dendritic cells in which MHC-II tran-
scription is normally repressed (18, 24). Similarly, TSA treat-
ment restored expression of MHC-II in a system where the
promoter was repressed in the absence of the Rb (36). To
address the role of deacetylation in MHC-II gene regulation by
IFN-, we treated HeLa cells with TSA (100 nM) after IFN-
FIG. 3. HDAC1 specifically represses inducible expression of endogenous MHC-II. (A) Real-time PCR analysis was performed to measure
endogenous mRNA levels of MHC-II in the presence of increasing amounts of HDAC1. HeLa cells were induced with IFN- (500 U/ml) for 24 h.
(B) Overexpression of HDAC1 does not inhibit CIITA mRNA expression. CIITA promoter IV mRNA was measured by real-time PCR.
(C) HDAC1 deacetylase activity is required for inhibition of CIITA-mediated activation of endogenous MHC-II. Real-time PCR analysis was
performed to measure endogenous mRNA levels of MHC-II in the presence of HDAC1. Equal amounts of CIITA and HDAC1 were transfected
into HeLa cells, and mRNA was isolated 24 h posttransfection. An HDAC1 deacetylase-defective mutant (H199F) failed to inhibit MHC-II
transcription. Values are means  standard errors of the means for three experiments. Samples were normalized to the number of 18S rRNA
copies.
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induction (500 U/ml) and measured MHC-II mRNA levels by
quantitative real-time PCR (Fig. 1). MHC-II expression was
greatly enhanced in the presence of TSA, suggesting that
deacetylases are involved in repressing MHC-II. Interestingly,
this enhancement occurred over a prolonged time course and
was not observed in the absence of IFN- (Fig. 1). These
results confirm previous findings for a suppressive role of
HDACs in MHC-II gene regulation (18, 24, 36).
HDAC1 and HDAC2 inhibit CIITA transactivation func-
tion. The observation that TSA enhances MHC-II expression
led us to hypothesize that HDACs are involved in repressing
MHC-II promoters. To identify the specific repressor com-
plexes, the two most abundant deacetylases, HDAC1 and
HDAC2, were tested in a transient-transfection experiment.
Cotransfection of either HDAC1 or HDAC2 with CIITA sig-
nificantly inhibited the activation of an MHC-II reporter (Fig.
2A), suggesting that both HDAC1 and HDAC2 are involved in
repressing MHC-II through CIITA. Moreover, this inhibition
was blocked by TSA and occurred in a dose-dependent manner
(data not shown). To further assess if CIITA is itself a target
for HDAC-mediated repression, a Gal4-CIITA construct was
used to activate a GAL4 promoter construct. In this system,
the GAL4 DNA binding domain within the fusion construct
binds to its cognate site on the GAL4 promoter, thus directly
FIG. 4. mSin3A mediates repression of CIITA transactivation function. (A) COS 7 cells were cotransfected with 100 ng of CIITA, increasing
amounts of mSin3A, and 0.5 g of DRA-luciferase reporter. Luciferase activity is reported as percent activation relative to that by CIITA alone.
(B) NcoR is not required for repression of MHC-II promoter activity. Transfection was performed as described for panel A. Values are shown
as mean percent relative luciferase activity  standard error of the mean for three experiments, each of which was repeated in triplicate.
FIG. 5. CIITA associates with HDAC1. (A) Myc-CIITA coimmunoprecipitates with Fg-HDAC1 and Fg-HDAC2. COS 7 cells were transfected
with equal amounts of Myc-CIITA and Fg-HDAC1 or Fg-HDAC2. The top panel shows the results for immunoprecipitation (IP) with anti-Fg M5
antibody, followed by immunoblotting with anti-Myc 9E10. CIITA interacted strongly with HDAC1 (lane 1) but only weakly with HDAC2 (lane
2). Association with NF-YA was also tested as a negative control (lane 3). Expression of Myc-CIITA was confirmed in the middle panel, and
expression levels of Fg-HDAC1, Fg-HDAC2, and Fg-NF-YA were confirmed in the bottom panels. (B) CIITA coimmunoprecipitates with
endogenous HDAC1 in 293T cells. Fg-CIITA was immunoprecipitated from 293T whole-cell lysates with anti-Fg M5 antibody. Endogenous
HDAC1 was detected in the top panel (lane 2) by immunoblotting with mouse anti-HDAC1 antibody (Santa Cruz Biotechnology). As a negative
control, a bead-only immunoprecipitation was also performed (lane 1). Expression levels of Fg-CIITA were confirmed in the bottom panel.
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recruiting the CIITA fusion partner to the promoter. A co-
transfection experiment shows that in the presence of either
HDAC1 or HDAC2, CIITA-mediated activation of the Gal4-
Luc reporter was significantly repressed (Fig. 2B). To test the
specificity of HDACs in this system, we examined the effect of
HDAC1 in Gal4-VP16-mediated activation (Fig. 2C). Overex-
pression of HDAC1 produced little effect on the activation of
the Gal4-Luc reporter by Gal4-VP16, indicating that HDAC1
specifically targets Gal4-CIITA.
To exclude the possibility that the results of Fig. 2A were
due to the suppression of CIITA expression through the activ-
ities of HDAC1 and HDAC2, we immunoblotted CIITA-trans-
fected COS 7 cell extracts using antibodies against the Flag
(Fg) epitope on CIITA (Fig. 2D). No dramatic change in
CIITA expression was found when HDAC1 or HDAC2 were
coexpressed (Fig. 2D, compare lane 1 with lanes 2 and 3,
respectively). These results strongly suggest that CIITA func-
tion, and not its expression, is a direct target of HDAC1 and
HDAC2. Furthermore, because in the Gal4 system MHC-II
specific transcription factors other than CIITA are not needed,
our data argue that repression can also occur in the absence of
YY1, which had been previously reported to inhibit inducible
expression of MHC-II in Rb-defective tumor cells (36). These
results provide evidence for an alternative, YY1-independent
mechanism of MHC-II down-regulation.
HDAC1 inhibits inducible expression of MHC-II. Our find-
ings indicate that HDAC1 and HDAC2 inhibit CIITA-medi-
ated activation of an MHC-II reporter. However, the reporter
assay system does not entirely reflect physiological chromatin
structural constraints. To address the effect of HDACs on
endogenous MHC-II, HeLa cells were transfected with in-
creasing dosages of HDAC1 after induction with IFN-, and
the levels of endogenous MHC-II mRNA were measured by
quantitative real-time PCR. HDAC1 significantly inhibited in-
ducible expression of endogenous MHC-II in a dose-depen-
dent manner (Fig. 3A). In contrast, the endogenous CIITA
transcript remained unaffected by HDAC1, indicating that the
reduction of MHC-II expression is not a consequence of re-
duced CIITA expression (Fig. 3B).
The possibility exists that HDAC1 is also repressing other
components of the IFN- signaling pathway. To address this
possibility, the requirement for IFN- mediators such as
STAT1 and IRF-1 was bypassed by the direct introduction of
CIITA into HeLa cells. CIITA transfection induced MHC-II
transcription as expected, and the cotransfection of HDAC1
greatly inhibited CIITA-mediated activation of endogenous
MHC-II as measured by real-time PCR (Fig. 3C). In contrast,
an HDAC1 deacetylase-defective mutant (H199F) (14, 15)
failed to inhibit MHC-II, indicating that repression of CIITA
function by HDAC1 requires an intact deacetylase domain.
mSin3A is required for MHC-II repression. HDAC1 and
HDAC2 generally exist in stable multicomponent complexes of
proteins which are recruited to various promoters through
interactions with DNA-binding factors (2, 8). A key compo-
nent of one such complex is the corepressor, mSin3A, which
bridges HDAC with different transcription factors and has
been shown to be important for repression mediated by
HDAC1 and HDAC2 (2, 8, 13). Although our results indicate
that HDAC1 deacetylase activity is required for repression of
MHC-II expression (Fig. 3C), a role for mSin3A in this process
cannot be excluded. This is a consideration because the de-
acetylase mutant tested in these experiments (H199F) is also
defective in mSin3A binding (13), indicating that this corepres-
sor might also be involved in down-regulating MHC-II gene
expression. To test if mSin3A is required for MHC-II repres-
sion, we performed transient-transfection assays. Cotransfec-
tion of CIITA and increasing amounts of mSin3A completely
repressed the activation of an MHC-II reporter (Fig. 4A). In
contrast, cotransfection of NcoR, a corepressor known to pref-
erentially associate with HDAC3 (20, 48), did not affect acti-
vation of the same reporter (Fig. 4B). These data suggest that
mSin3A-associated HDAC1 complexes are required for inhi-
bition of MHC-II expression mediated by CIITA.
CIITA interacts with both HDAC1 and HDAC2 in vivo. The
results described to this point suggest the possibility that
HDAC1 and HDAC2 may interact with CIITA. To test this
hypothesis, Myc-CIITA was cotransfected with either Fg-
FIG. 6. Overexpression of HDAC1 or HDAC2 does not change
the nuclear localization of CIITA. COS 7 cells were transfected with
1 g of GFP-CIITA and 3 g of HDAC1, HDAC2, or empty vector
(pcDNA3). Immunofluorescence was detected 24 h posttransfection.
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HDAC1 or Fg-HDAC2 in COS 7 cells. HDAC1 or HDAC2
was immunoprecipitated with an anti-Fg antibody, and associ-
ated CIITA was detected by immunoblotting with anti-Myc
antibody. Following immunoblotting, we detected efficient co-
precipitation of CIITA with HDAC1 and a much weaker as-
sociation with HDAC2 (Fig. 5A, upper panel, lanes 1 and 2).
To ensure that these interactions are specific for HDAC1 and
HDAC2, we also tested another nuclear NF-YA MHC-II en-
hanceosome-associated protein and observed no detectable
association (Fig. 5A, upper panel, lane 3). To assure that no
variation in protein expression existed, proteins in the lysates
were assayed by immunoblotting prior to immunoprecipitation
(Fig. 5A, lower panels).
The above-described experiment relied on an overexpres-
sion system of both CIITA and HDAC1 or HDAC2. The
endogenous level of CIITA protein is extremely low even in
antigen-presenting cells; however, endogenous HDAC1 can
be detected by immunoprecipitation (55, 56). We examined
the interaction of epitope-tagged CIITA with endogenous
HDAC1. To this end, Fg-CIITA from transiently transfected
293T cells was immunoprecipitated with anti-Fg antibody and
immunoblotted with antibodies against HDAC1. Endogenous
HDAC1 was found to coprecipitate with CIITA (Fig. 5B, up-
per panel, lane 2), arguing for a physiological role of these
interactions in MHC-II gene control. Equal expression of
Fg-CIITA was verified by immunoblotting of lysates prior to
immunoprecipitation (Fig. 5B, lower panel).
HDAC1 does not affect localization of CIITA. CIITA local-
izes to both the nucleus and the cytoplasm. Nuclear import of
CIITA is critical for MHC-II activation and has been shown to
be regulated by a number of nuclear localization signals (4, 44).
In addition, another study has reported that CIITA can be
acetylated by pCAF, thus facilitating its nuclear import (44).
Therefore, it is possible that HDAC1 and HDAC2 repress
MHC-II by interfering with CIITA localization. To investigate
this scenario, we transfected COS 7 cells with GFP-CIITA and
examined its localization pattern in the presence of either
HDAC1 or HDAC2 (Fig. 6). Expression of either deacetylase
did not alter nuclear localization of CIITA. These results in-
dicate that MHC-II repression by HDAC1 and HDAC2 is not
likely due to changes in the subcellular distribution of CIITA.
TSA enhances association of CIITA with NF-YB and RFX5.
Several reports have demonstrated extensive protein-protein
interactions between CIITA and components of the MHC-II
enhanceosome complex, RFX5 and NF-YB/C (26, 42, 58).
Because these interactions are critical for MHC-II expression,
one could argue that inadequate assembly of this transcription
complex mediated by HDAC1 and HDAC2 is inhibitory for
efficient promoter activation. To assess the role of HDAC
activity in enhanceosome assembly, the interaction of CIITA
with RFX5 or NF-YB in vivo was tested in the presence or
absence of TSA, a broad inhibitor of HDACs. Myc-CIITA was
cotransfected with either Fg-NF-YB or Fg-RFX5 in COS 7
cells. Fg-NF-YB or Fg-RFX5 was immunoprecipitated with an
anti-Fg antibody, and associated CIITA was detected by im-
munoblotting with anti-Myc antibody. The general inhibition
of deacetylase activity greatly enhanced association of CIITA
with both NF-YB (Fig. 7A, upper panel, compare lanes 1 and
2) and RFX5 (Fig. 7B, upper panel, compare lanes 1 and 2).
Equal expression of CIITA, NF-YB, and RFX5 was verified by
immunoblotting of lysates prior to immunoprecipitation (Fig.
7A and B, lower panels). These results strongly suggest that
HDAC activity inhibits critical interactions of CIITA with
MHC-II DNA-binding factors.
TSA promotes the stable association of CIITA and MHC-II
enhanceosome factors with the endogenous MHC-II promoter.
Extensive biochemical studies have demonstrated that MHC-II
transcription factors are involved in multiple protein-protein
FIG. 7. TSA promotes association of CIITA with NF-YB and RFX5. (A) TSA enhances interaction of CIITA with NF-YB (compare lanes 1
and 2). COS 7 cells were transfected with equal amounts of Myc-CIITA and Fg-NF-YB and treated with 300 nM TSA. The top panel shows the
results for immunoprecipitation (IP) with anti-Fg M5 antibody, followed by immunoblotting with anti-Myc 9E10. Expression of Myc-CIITA in
lysates was confirmed in the middle panel, whereas expression levels of Fg-NF-YB in lysates were confirmed in the bottom panel. (B) TSA
enhances interaction of CIITA with RFX5 (compare lanes 1 and 2). Expression and detection of Myc-CIITA interaction with Fg-RFX5 was
performed using the same procedure as described for panel A. Expression levels of Myc-CIITA and Fg-RFX5 were confirmed in the middle and
bottom panels, respectively.
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interactions that are critical for CIITA recruitment and pro-
moter activation (26, 42, 58). Because TSA promotes the as-
sociation of CIITA with RFX5 and NF-YB (Fig. 7), we pre-
dicted that enhanced recruitment of CIITA to the MHC-II
promoter would be facilitated by TSA treatment as well. To
test this hypothesis, we investigated the effect of TSA on the
association of CIITA with the MHC-II promoter by ChIP
analysis. Fg-tagged CIITA was transiently transfected into
293T cells, and immunoprecipitations were performed with
anti-Fg antibodies. DNA isolated from immunoprecipitated
chromatin was analyzed by real-time PCR. ChIP analysis dem-
onstrated that TSA greatly increased CIITA association with
the MHC-II promoter (Fig. 8A), suggesting that the inhibition
of HDAC activity is important for CIITA recruitment to the
promoter. To ensure that the TSA effect specifically occurs at
CIITA-dependent promoters, we performed PCR analysis on
the immunoprecipitated DNA with primers for the -actin
promoter. CIITA did not interact with the -actin promoter in
the presence of TSA (Fig. 8B). Furthermore, to exclude the
possibility that the enhanced association of CIITA with the
promoter was simply a result of elevated CIITA protein levels
in the presence of TSA, we immunoblotted transfected 293T
cell extracts using antibodies against the Fg epitope on CIITA
and found that CIITA expression was not altered by TSA (Fig.
8C).
As previously mentioned, CIITA is recruited to MHC-II
promoters via multiple interactions with components of the
MHC-II enhanceosome. One mechanism by which TSA en-
hances CIITA recruitment to the MHC-II promoter could
involve increasing enhanceosome complex assembly at the pro-
moter. To test this hypothesis, we transfected 293T cells with
Fg-NF-YB or Fg-RFX5, treated the cells with TSA, and per-
formed ChIP assays (Fig. 9). Our results indicate that TSA
enhanced the binding of both NF-YB (Fig. 9A) and RFX5
(Fig. 9B) to the MHC-II promoter, without affecting the level
of their expression (data not shown). It should be noted that
the fold increase in association of NF-YB and RFX5 with the
promoter is less pronounced (Fig. 9) than that of CIITA (Fig.
8A). As controls, TSA did not enhance association of NF-YB
or RFX5 with the -actin promoter (Fig. 9, bottom panels).
This finding is consistent with those of previous studies dem-
onstrating that multiple interactions of CIITA with MHC-II
DNA-binding factors have a synergistic effect on recruitment
of CIITA to MHC-II promoters (26) but additionally shows
that TSA enhances these interactions at the promoter.
TSA enhances IFN--dependent H3 acetylation at the
MHC-II promoter. A majority of the above-described experi-
ments utilized overexpressed CIITA. To further explore the
effect of TSA and HDACs on MHC-II promoters in a physi-
ologic setting, we reexamined the IFN- induction of MHC-II.
Hyperacetylation of lysines in the NH2-terminal tails of core
histones has been strongly correlated with active genes and has
been shown to be required for an “open” chromatin confor-
mation, facilitating promoter association of transcription fac-
tors (33) Analogously, hypoacetylation at specific promoters
has been correlated with recruitment of HDAC complexes to
repressed genes (33). Our findings indicate that blocking of
HDAC activity by TSA enhances IFN--inducible expression
of endogenous MHC-II (Fig. 1). An additional mechanism by
which TSA increases MHC-II expression could involve de-
creasing the ratio of HDAC-to-HAT activities, thus causing
enhanced acetylation levels of histone H3. To test this possi-
bility, we induced HeLa cells with IFN- (500 U/ml), treated
these cells with TSA (100 nM), and performed ChIP assays
using anti-acetyl H3 antibodies. As predicted from a previous
report (3), IFN- induced a fivefold increase in H3 acetylation
at the MHC-II promoter (Fig. 10A). Significantly, TSA further
enhanced IFN--dependent acetylation of H3 (Fig. 10A) at the
promoter region. These experiments support the model where
IFN- increases histone acetylation and also indicate that
IFN- cannot completely remove all residual HDAC activity
from the promoter. Instead, TSA is necessary to inhibit all
FIG. 8. (A) TSA enhances CIITA recruitment to the MHC-II pro-
moter. 293T cells were transfected with Fg-CIITA and treated with 300
nM TSA. Chromatin immunoprecipitation was performed using an-
ti-Fg M5. MHC-II promoter DNA was detected by quantitative real-
time PCR. Data are presented as increases compared to results with
untreated cells. Real-time PCR values were determined by subtracting
values obtained from bead-only immunoprecipitations and normaliz-
ing to the total amount of MHC-II promoter DNA added to the
immunoprecipitation reaction (input). Data shown are representative
of three independent experiments. (B) TSA does not promote associ-
ation of CIITA with the -actin promoter. Chromatin was prepared
from transiently transfected 293T cells as was done for panel A. PCR
was performed to detect -actin promoter DNA sequences. Input
represents 1% of the total chromatin introduced into each immuno-
precipitation reaction. (C) TSA does not affect CIITA protein levels.
293T cells were transfected with Fg-CIITA and treated with TSA as for
panel A. CIITA was detected by Western analysis anti-Fg antibody. As
a loading control we also immunoblotted with antibodies against actin
(bottom panel).
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HDAC activity, leading to a further enhancement of histone
acetylation and gene expression. The acetylation level of his-
tone H3 at the -actin promoter did not change in response to
IFN-, again indicating the specificity of these results (Fig.
10B). These data indicate that the induction of MHC-II by
IFN- is modulated by HDAC activity.
DISCUSSION
Precise control of MHC-II expression ensures appropriate
responses to pathogens while minimizing collateral damage to
host tissue. The regulation of MHC-II genes resides predom-
inantly at the level of transcription and is controlled by the
class II transactivator, CIITA. Multiple interactions of CIITA
with site-specific DNA-binding factors, components of the
basal transcription machinery, and chromatin modifiers have
been shown to play a critical role in MHC-II activation (47). In
addition, a key report has demonstrated the role of histone
acetylation in MHC-II regulation (3). However, far less is
known about the chromatin complexes that are involved in
repression of MHC-II. This work shows that HDACs are key
players in the control of MHC-II transcription, CIITA func-
tion, and association with other transcription factors in lysates
and on promoters.
Previous observations led us to hypothesize that HDACs
might be involved in inhibition of MHC-II (24, 36). This
study examined the role of HDACs, specifically HDAC1 and
HDAC2, in MHC-II gene regulation. We demonstrated that
HDACs inhibit IFN- activation of MHC-II by inhibiting the
transactivation function of CIITA. This inhibition requires an
intact HDAC1 deacetylase domain and can also be mediated
by the corepressor mSin3A. Furthermore, CIITA associated
with both exogenous and endogenous HDAC1, indicating that
direct or indirect CIITA-HDAC interactions may occur. Fi-
nally, inhibition of HDAC activity by TSA dramatically en-
hances the interaction of CIITA with NF-YB and RFX5 and
has a profound effect on the recruitment of CIITA to the
endogenous MHC-II promoter. These results suggest that
HDAC1 may be recruited to the MHC-II promoter to cause
gene repression via the disruption of MHC-II enhanceosome
formation (Fig. 11).
Many possible scenarios could explain the observation that
blocking HDAC activity enhances the formation of the
CIITA–NF-YB–RFX5 complex. Both CIITA (44) and NF-Y
(19) are known substrates of HDACs. Treatment with TSA
could increase acetylation of CIITA and/or NF-Y, promoting
their association and interaction with the MHC-II promoter.
Conversely, it is possible that HDAC1 and/or HDAC2 directly
targets CIITA or NF-Y for deacetylation and affect their in-
teraction potential or ability to bind DNA. Acetylation of
RFX5 is also possible; however, this has not been tested. In
agreement with this hypothesis, we demonstrated that inhibi-
tion of deacetylase activity by TSA promotes the ability of both
FIG. 9. TSA promotes a stable association of RFX5 and NF-YB with the MHC-II promoter. (A) TSA enhances NF-YB association with the
MHC-II promoter (top panel) but not the -actin promoter (bottom panel). 293T cells were transiently transfected with Fg-NF-YB and treated
with TSA (300 nM). Chromatin immunoprecipitation was performed using anti-Fg M5. MHC-II promoter sequences were detected by quantitative
real-time PCR, and -actin promoter was detected by PCR. Data are presented as increases compared to results with untreated cells. Real-time
PCR values were determined by subtracting values obtained from bead-only immunoprecipitations and normalizing to the total amount of MHC-II
promoter DNA added to the immunoprecipitation reaction (Input). (B) TSA enhances RFX5 association with the MHC-II promoter (top panel).
293T cells were transfected with Fg-RFX5 and treated with TSA as described for panel A. Chromatin immunoprecipitation was performed as for
panel A. Real-time PCR values were determined as for panel A. Association of RFX5 with the -actin promoter was not detected (bottom panel).
VOL. 23, 2003 HDAC1 AND HDAC2 REPRESS MHC-II AND CIITA 3099
NF-YB and RFX5 to associate with the MHC-II promoter.
However, the order of events is not clear from our data: en-
hanced recruitment of NF-YB and RFX5 may promote CIITA
recruitment; alternatively, enhanced CIITA may stabilize the
NF-YB–RFX5 complex. Recent reports have demonstrated
that HDAC1 deacetylates nonhistone proteins, such as p53,
which inhibits its transactivation function (32).
Another possibility is that HDAC1 and HDAC2 disrupt
MHC-II enhanceosome formation by removing CIITA from
the transcription complex. This hypothesis is supported by the
observation that CIITA interacts with HDAC1 in vivo, al-
though it is currently unclear whether this association is direct
or mediated by other repressors, such as mSin3A. Our data
show a more pronounced effect of mSin3A than HDAC1 or
HDAC2 on MHC-II repression. This implies that HDAC1
may indirectly affect CIITA function via its binding to mSin3A.
Significantly, NcoR, which is preferentially assembled into
HDAC3 complexes, failed to repress MHC-II, suggesting that
CIITA specifically associates with HDAC1. As an alternate
scenario, it is plausible that HDAC1 and HDAC2 or other
HDACs interact with NF-YB and RFX5, thus altering their
functional activity or association with CIITA. However, we
have failed to detect an association between HDAC1/HDAC2
and NF-YB or RFX5 (data not shown), indicating that this is
a less likely possibility.
An additional mechanism by which HDAC1 and HDAC2
mediate MHC-II repression could involve the deacetylation of
histones at the promoter. The primary activity of HDAC1 and
HDAC2 is to deacetylate histones H3 and H4, providing the
basis for transcriptional repression of genes (49). Our results
demonstrate that HDAC1 and HDAC2 significantly inhibit
CIITA-mediated activation of MHC-II; presumably this can
occur via recruitment of HDAC1 and HDAC2 repressor com-
plexes to the promoter. Although the association of either
HDAC1 or HDAC2 with the MHC-II promoter has not yet
been demonstrated, it is likely that these enzymes deacetylate
histones H3 and H4 at specific regions of the MHC-II pro-
moter, thus disrupting transcription factor association and in-
hibiting gene expression. Our data further demonstrates that
broad inhibition of HDAC activity by TSA additionally en-
hanced H3 acetylation at the endogenous MHC-II promoter
after IFN- induction. This suggests that HDAC is present at
FIG. 10. (A) TSA enhances IFN--dependent acetylation of his-
tone H3 (AcH3) at the MHC-II promoter. HeLa cells were induced
with IFN- (500 U/ml) for 24 h and treated with 100 nM TSA. Chro-
matin immunoprecipitation was performed using anti-acetyl H3. Im-
munoprecipitated DNA was analyzed by real-time PCR, and values
were determined as described in the legend for Fig. 8A. (B) IFN-
does not affect H3 acetylation at the -actin promoter. Chromatin
immunoprecipitation was performed as for panel A, and DNA was
analyzed by PCR. Input represents 1% of the total chromatin intro-
duced into each immunoprecipitation reaction.
FIG. 11. Model for the role of HDACs in MHC-II regulation. In
the absence of inducing signals, such as IFN- signals, histones are hypo-
acetylated at the MHC-II promoter due to the presence of HDAC and
absence of HAT activity. Association of MHC-II DNA-binding factors
with the MHC-II promoter is observed at a low level. When CIITA is
induced by IFN-, it associates with MHC-II transcription factors, such
as RFX5 and NF-YB, and HATs. These interactions open chromatin
and correlate with increased acetylated H3. If HDAC activity is inhib-
ited by TSA, CIITA–NF-YB–RFX5 interactions are further stabilized
and MHC-II enhanceosome formation is enhanced. Histones also be-
come hyperacetylated, and maximal activation is achieved. At the end
of the induction phase, HDAC may interact with CIITA, resulting in
the disassembly of the entire enhanceosome complex.
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the MHC-II promoter and that even under strong cytokine
induction, the promoter still retains some associated HDAC
activity. Whether CIITA recruits HDAC activity to MHC-II
promoters remains to be explored. Furthermore, alternative
mechanisms of CIITA-independent HDAC recruitment can-
not be excluded. One such mechanism could involve YY1-
mediated repression (36) and could explain the up-regulation
of MHC-II expression observed in CIITA-negative cells in the
presence of TSA (24).
One caveat with many of the above scenarios is that the
hypothesis is driven by the inhibition of CIITA function by
HDACs. However, it is likely that bidirectional effects are
occurring, and CIITA also affects the function of HDACs.
For example, the interaction of HDAC1 with CIITA may
well cause a reversed outcome, where CIITA removes
HDAC1 from the promoter, allowing histones to be acetylated
and the promoter to be open. This then allows more stable
formation of the NF-YB–RFX5 enhanceosome complex which
is further enhanced by interaction with CIITA.
One important observation is that CIITA can associate with
both HATs (CBP/p300, pCAF) (7, 16, 43, 44, 59) and HDACs
(HDAC1 and HDAC2) (this study), suggesting that CIITA
might act as a molecular switch, central to these two opposing
states of MHC-II transcription. That CIITA may serve as a
mediator that leads to the eventual extinction of MHC-II gene
transcription after the initial stage of gene activation is accom-
plished is an unorthodox possibility. If this is the case, it is
possible that different posttranslational modifications in CIITA
modulate its association with either activator or repressor com-
plexes. In support of this model, it has recently been demon-
strated that phosphorylation of the p65 NF-	B subunit deter-
mines whether it associates with CBP or HDAC1, ensuring
proper regulation of p65-dependent genes (57).
In summary, our results show that HDAC1 and HDAC2
suppress activation of an MHC-II reporter construct and the
endogenous MHC-II promoter by both IFN- and CIITA (Fig.
11). The specific involvement of HDAC1 and HDAC2 is dem-
onstrated here, although other HDACs are likely involved but
have not yet been examined. The balance of HDAC and HAT
activities likely determines the extent of enhanceosome forma-
tion involving CIITA, NF-YB, and RFX5. Interestingly, even
in the presence of a strong cytokine inducer such as IFN-, a
basal level of HDACs still appears to be exerting its effect on
the MHC-II promoter in terms of both gene induction and
histone acetylation. These results suggest that CIITA may be a
central molecular switch for MHC class II gene regulation
through its interactions with both HATs and HDACs.
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